Novo looks at Victoza in fatty liver disease; FDA flags SGLT2 inhibitors for potentially high blood acid levels;

> Novo Nordisk ($NVO) is examining recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease. Report

> A new lawsuit claims Blue Cross has withheld hep C cure Harvoni for financial reasons. Release

> The FDA has warned that a new class of Type 2 diabetes drugs--SGLT2 inhibitors--may cause dangerously high levels of blood acids that could require hospitalization. Report

> A lawsuit claims the FDA overstepped its bounds by deciding two generic drugs used to treat ADHD should no longer be substituted for Johnson & Johnson's ($JNJ) widely used Concerta. More

> Boehringer Ingelheim has new Phase II study data for idiopathic pulmonary fibrosis (IPF) treatment Ofev that show its efficacy and safety in a broader range of patients. More

And Finally... Australia's Sirtex may be on Bayer's M&A radar as the two companies focus in on radiation treatments for liver cancers. Story

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.